Multicentric validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring in two prospective cohorts of patients.
作者信息
Vasdev Nikhil
机构信息
Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK.
School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire, UK.
出版信息
Br J Cancer. 2023 Apr;128(6):929. doi: 10.1038/s41416-023-02142-z. Epub 2023 Mar 1.
Abstract
摘要
相似文献
1
Multicentric validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring in two prospective cohorts of patients.基于BC - 116和BC - 106尿液肽生物标志物组的列线图在两个前瞻性患者队列中用于膀胱癌诊断和监测的多中心验证
Br J Cancer. 2023 Apr;128(6):929. doi: 10.1038/s41416-023-02142-z. Epub 2023 Mar 1.
2
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients.基于 BC-116 和 BC-106 尿肽生物标志物的膀胱癌诊断检测的多中心验证：两项前瞻性患者队列研究。
Br J Cancer. 2022 Nov;127(11):2043-2051. doi: 10.1038/s41416-022-01992-3. Epub 2022 Oct 3.
3
Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.基于尿液的肽生物标志物panel 的开发和验证，用于在多中心研究中检测膀胱癌。
Clin Cancer Res. 2016 Aug 15;22(16):4077-86. doi: 10.1158/1078-0432.CCR-15-2715. Epub 2016 Mar 29.
4
Nomograms including the UBC Rapid test to detect primary bladder cancer based on a multicentre dataset.基于多中心数据集的包含UBC快速检测法的列线图用于检测原发性膀胱癌。
BJU Int. 2022 Dec;130(6):754-763. doi: 10.1111/bju.15677. Epub 2022 Jan 11.
5
Proteomic research and diagnosis in bladder cancer: state of the art review.膀胱癌的蛋白质组学研究与诊断：最新综述
Int Braz J Urol. 2021 May-Jun;47(3):503-514. doi: 10.1590/S1677-5538.IBJU.2021.99.02.
6
Urine cell-based DNA methylation classifier for monitoring bladder cancer.基于尿液细胞的 DNA 甲基化分类器用于膀胱癌监测。
Clin Epigenetics. 2018 May 30;10:71. doi: 10.1186/s13148-018-0496-x. eCollection 2018.
7
A urinary microRNA (miR) signature for diagnosis of bladder cancer.用于诊断膀胱癌的尿液微小RNA（miR）特征
Urol Oncol. 2018 Dec;36(12):531.e1-531.e8. doi: 10.1016/j.urolonc.2018.09.006. Epub 2018 Oct 12.
8
The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review.尿液甲基化标志物诊断膀胱癌的准确性：系统评价。
Epigenomics. 2018 May;10(5):673-687. doi: 10.2217/epi-2017-0156. Epub 2018 Apr 25.
9
Bladder cancer survival nomogram: Development and validation of a prediction tool, using the SEER and TCGA databases.膀胱癌生存列线图：利用监测、流行病学和最终结果（SEER）数据库及癌症基因组图谱（TCGA）数据库开发并验证一种预测工具
Medicine (Baltimore). 2019 Nov;98(44):e17725. doi: 10.1097/MD.0000000000017725.
10
Derivation and Comprehensive Analysis of Aging Patterns in Patients with Bladder Cancer.膀胱癌患者衰老模式的推导与综合分析
Dis Markers. 2021 Oct 21;2021:3385058. doi: 10.1155/2021/3385058. eCollection 2021.
引用本文的文献
1
Risk factors analysis and risk prediction model for failed back surgery syndrome: A prospective cohort study.腰椎手术失败综合征的危险因素分析及风险预测模型：一项前瞻性队列研究。
Heliyon. 2024 Nov 22;11(1):e40607. doi: 10.1016/j.heliyon.2024.e40607. eCollection 2025 Jan 15.
2
Peptide Biomarkers - An Emerging Diagnostic Tool and Current Applicable Assay.肽生物标志物——一种新兴的诊断工具及当前适用的检测方法。
Curr Protein Pept Sci. 2025;26(3):167-184. doi: 10.2174/0113892037315736240907131856.
3
Nomogram-based risk assessment for emergency cervical cerclage failure in patients with cervical insufficiency.基于列线图的宫颈机能不全患者急诊宫颈环扎失败风险评估
Heliyon. 2024 Jun 13;10(13):e32923. doi: 10.1016/j.heliyon.2024.e32923. eCollection 2024 Jul 15.
4
Risk factors analysis and risk prediction model construction of non-specific low back pain: an ambidirectional cohort study.非特异性下腰痛的危险因素分析及风险预测模型构建：一项双向队列研究。
J Orthop Surg Res. 2023 Jul 29;18(1):545. doi: 10.1186/s13018-023-03945-9.
本文引用的文献
1
Urinary biomarkers to mitigate diagnostic delay in bladder cancer during the COVID-19 era.用于减轻 COVID-19 时代膀胱癌诊断延误的尿液生物标志物。
Nat Rev Urol. 2021 Apr;18(4):185-187. doi: 10.1038/s41585-020-00419-z.
2
Urinary biomarkers in bladder cancer: A review of the current landscape and future directions.膀胱癌的尿生物标志物：当前研究现状及未来方向综述。
Urol Oncol. 2021 Jan;39(1):41-51. doi: 10.1016/j.urolonc.2020.08.016. Epub 2020 Sep 9.
3
Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.尿细胞学及其他膀胱癌尿液生物标志物的敏感性和特异性的前瞻性分析。
Urol Oncol. 2015 Feb;33(2):66.e25-31. doi: 10.1016/j.urolonc.2014.06.008. Epub 2014 Jul 15.
4
Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement.尿细胞学检查中尿路上皮癌分级的准确性：观察者间和观察者内一致性分析
Int J Clin Exp Pathol. 2012;5(9):882-91. Epub 2012 Oct 20.
5
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses.常用膀胱肿瘤标志物与细胞学检查的敏感性和特异性：一项全面文献综述与荟萃分析的结果
Urology. 2003 Jan;61(1):109-18; discussion 118. doi: 10.1016/s0090-4295(02)02136-2.
Zotero 插件